RxDoctor Payments Data

Laura Vandenberg

Family · Elverson, PANPI 1831859834

Payments from drug & device makers

$1,547in general payments, 2019–2025

Across 56 payments — averaging $27.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$92
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$85
  • Novartis$68
  • Pfizer$65
  • AstraZeneca$38
  • plus $51 from 2 others

What the payments were for

  • Travel & lodging$28218%
  • Food & beverage$1,26582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,547 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,633
Medicare patients
285
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban330$316,881
EntrestoSacubitril/Valsartan255$263,230
JardianceEmpagliflozin134$114,295
FarxigaDapagliflozin Propanediol84$65,854
XareltoRivaroxaban58$61,108
CorlanorIvabradine Hcl17$10,143
Repatha SureclickEvolocumab17$9,329
Metoprolol Succinate393$6,453
Torsemide175$5,027
Potassium Chloride171$3,903
Furosemide465$2,639
Bumetanide44$2,257
Isosorbide Dinitrate23$2,074
Atorvastatin Calcium129$1,707
Amiodarone Hcl102$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$316,881330 claims
NovartisEntresto$68$263,230255 claims
AstraZenecaFarxiga$38$65,85484 claims
Johnson & JohnsonXarelto$30$61,10858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.

Other family in Elverson

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →